Endocyte insiders to reap millions from Novartis deal
Executives and directors of the West Lafayette-based biotech hold nearly 9 percent of Endocyte stock, worth about $177 million, based on the deal price of $24 a share.
Executives and directors of the West Lafayette-based biotech hold nearly 9 percent of Endocyte stock, worth about $177 million, based on the deal price of $24 a share.
For at least a year, county officials have debated how best to pay for the county’s 911 communications operation going forward.
Look at the future prospects, not the losses, says the CEO of a newly listed Chinese biotech company that’s developing anti-cancer drugs with Indianapolis-based Eli Lilly and Co.
On average, the premium for typical plans in the 39 states that use the federal healthcare.gov website will drop 1.5 percent.
Two reports, sponsored by the Richard M. Fairbanks Foundation, say the state should not let up in fighting twin scourges that claim thousands of lives and cost billions of dollars in health care costs and lost productivity.
Much of the insurance left on the Affordable Care Act marketplaces limits patients to narrow networks of hospitals or doctors and provides no coverage outside those networks.
President Donald Trump said he was “taking aim at the global freeloading that forces American consumers to subsidize lower prices in foreign countries through higher prices in our country.”
President Donald Trump is linking the drug prices Americans complain about to one of his longstanding grievances: foreign countries the president says are taking advantage of U.S. research breakthroughs.
Indiana University Health Physicians is setting its sights on one of the state’s last independent specialty holdouts, the neurosurgical Goodman Campbell Brain and Spine.
The plan approved by Purdue trustees on Oct. 12 met widespread opposition from faculty and staff.
The experimental drug eased arthritis pain in hard-to-treat patients without major safety concerns, a key step in creating a new class of medications that may one day offer an alternative to narcotics.
The Treasury pilot program implements broader powers Congress granted this year to the Committee on Foreign Investment in the U.S., a panel of officials who review foreign takeover of American firms and can recommend that the president block deals that threaten national security.
The West Lafayette biotech firm’s stock traded as low as $1.41 last fall, following multiple setbacks and restructurings. But the stock had soared to $24 Thursday morning after news that it would be acquired by Novartis.
One year ago, Indiana-based Endocyte Inc. bought the rights to a prostate cancer treatment for $12 million, plus future considerations. On Thursday, Novartis AG agreed to pay almost 200 times that amount to acquire Endocyte and the experimental therapy.
The standalone, two-story facility is expected to offer a wide array of inpatient and outpatient services, including addiction treatment, counseling and psychiatric intensive care.
The drug industry's main trade group said drug companies are only willing to disclose the prices on their websites, not in commercials, and they'll start doing that next spring.
Shares in Elanco Animal Health Inc. slipped as much as 3.3 percent Monday morning after lead managers and other banks involved in its recent initial public offering started coverage on the animal health company.
An Indianapolis-based company has signed a deal with national mail-order pharmacy GoGoMeds that officials project will help double its local workforce—to about 250—within five years.
The physicians’ group claims the Connersville health system misled it on patient volumes and has refused to adjust a subsidy to make up the difference.
The Justice Department’s approval clears the way for a merger that will create a health care giant with a hand in insurance, prescription-drug benefits and drugstores across the United States.